Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi's Consumer Business Starts 2017 With 'Reassuring' Momentum

Executive Summary

Sanofi consumer products head Alan Main says BI's brands will "lift Sanofi into leadership positions in attractive OTC categories, namely the vitamins and minerals supplements market, digestive products, cough and cold as well as pain medications."

You may also be interested in...



Emerging Markets Are Next Turn In Sanofi Consumer Health Growth

Sanofi's consumer health sales were off 1%, at $1.4bn, during its latest quarter compared to a corresponding year-ago period, with inclusion of Boehringer's OTC drug and nutritional product brand revenues. But for Sanofi's legacy consumer products only, sales were up 42.5%.

Emerging Markets Are Next Turn In Sanofi Consumer Health Growth

Sanofi's consumer health sales were off 1%, at $1.4bn, during its latest quarter compared to a corresponding year-ago period, with inclusion of Boehringer's OTC drug and nutritional product brand revenues. But for Sanofi's legacy consumer products only, sales were up 42.5%.

Returns From Sanofi Consumer Expansion Could Point To More

The French pharma's strategy of driving consumer health business growth by expanding the product lineup played out during the first quarter with the launch of OTC switch Xyzal Allergy and with further integration of OTC drug and vitamin brands recently acquired from Boehringer Ingelheim.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134409

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel